These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39468581)

  • 1. Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation.
    Zhang C; Wang X; Yi H; Wang Y; Yan Z; Zhou J; Yang T; Liang A; Wang Z; Ma Y; Wen Q; Gao L; Gao L; Kong P; Tan X; Jiang E; Zhang X
    J Hematol Oncol; 2024 Oct; 17(1):103. PubMed ID: 39468581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
    Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2021; 12():605766. PubMed ID: 34025637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Zhuo YQ; Tu SF; Zhou X; Yang JL; Zhou LJ; Huang R; Huang YX; Li MF; Jin B; Wang B; Li SQ; Yuan ZT; Zhang LH; Liu L; Wang SB; Li YH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):74-81. PubMed ID: 38527842
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
    Zhang X; Yang J; Li J; Li W; Song D; Lu XA; Wu F; Li J; Chen D; Li X; Xu Z; Liu S; Li Z; Ying K; Lu P
    Cancer Immunol Immunother; 2022 Mar; 71(3):689-703. PubMed ID: 34365516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
    [No Abstract]   [Full Text] [Related]  

  • 8. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
    Aldoss I; Shan H; Yang D; Clark MC; Al Malki M; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
    Transplant Cell Ther; 2024 Aug; 30(8):788.e1-788.e9. PubMed ID: 38876428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
    Hay KA; Gauthier J; Hirayama AV; Voutsinas JM; Wu Q; Li D; Gooley TA; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Schoch G; Chapuis AG; Till BG; Kiem HP; Ramos JD; Shadman M; Cassaday RD; Acharya UH; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(15):1652-1663. PubMed ID: 30728140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation.
    Deng L; Yu X; Song X; Guan R; Li W; Hou Y; Shao Y; Zhao Y; Wang J; Liu Y; Xiao Q; Xin B; Zhou F
    Cytotherapy; 2024 Nov; 26(11):1301-1307. PubMed ID: 38888526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
    Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tan X; Wang XQ; Zhang C; Zhao XL; Yao H; Chen G; Ma YY; Wen Q; Gao L; Gao L; Kong PY; Shen Y; Zhang X; Lou SF
    Curr Med Sci; 2023 Aug; 43(4):733-740. PubMed ID: 37330456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-T Therapy Followed by Hematopoietic Stem Cell Transplantation Can Improve Survival in Children Relapsed/Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia.
    Li Y; Hu GH; Xu LP; Zhang XH; Liu KY; Suo P; Wang Y; Cheng YF; Huang XJ
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):241-247. PubMed ID: 38652054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.